Eledon Pharmaceuticals, Inc. (ELDN)

NASDAQ: ELDN · IEX Real-Time Price · USD
2.42
+0.05 (1.94%)
Mar 30, 2023, 10:27 AM EDT - Market open
1.94%
Market Cap 33.24M
Revenue (ttm) n/a
Net Income (ttm) -38.39M
Shares Out 13.76M
EPS (ttm) -2.67
PE Ratio n/a
Forward PE 2.19
Dividend n/a
Ex-Dividend Date n/a
Volume 15,713
Open 2.45
Previous Close 2.37
Day's Range 2.36 - 2.68
52-Week Range 1.90 - 4.14
Beta 2.04
Analysts Buy
Price Target 18.56 (+668.21%)
Earnings Date May 10, 2023

About ELDN

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 12
Stock Exchange NASDAQ
Ticker Symbol ELDN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ELDN stock is "Buy." The 12-month stock price forecast is $18.56, which is an increase of 668.21% from the latest price.

Price Target
$18.56
(668.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET

6 days ago - GlobeNewsWire

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the upco...

1 month ago - GlobeNewsWire

Eledon Pharmaceuticals Provides Business and Pipeline Updates

Company plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation

2 months ago - GlobeNewsWire

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant Trials Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant Trials

3 months ago - GlobeNewsWire

Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results

Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant

4 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

5 months ago - GlobeNewsWire

Eledon Pharmaceuticals Announces Upcoming Presentations at ASN's Kidney Week 2022 and NEALS

IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society of ...

5 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a ...

6 months ago - GlobeNewsWire

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's In...

7 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences

IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor conferences:

7 months ago - GlobeNewsWire

Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results

Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients

8 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

Management to host conference call and webcast at 4:30 pm ET

8 months ago - GlobeNewsWire

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inn...

8 months ago - GlobeNewsWire

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inn...

10 months ago - GlobeNewsWire

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

IRVINE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inno...

10 months ago - GlobeNewsWire

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022

11 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET

11 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of in...

1 year ago - GlobeNewsWire

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of in...

1 year ago - GlobeNewsWire

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022

1 year ago - GlobeNewsWire

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

1 year ago - GlobeNewsWire

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inn...

1 year ago - GlobeNewsWire

Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences

IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inn...

1 year ago - GlobeNewsWire

Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results

Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022

1 year ago - GlobeNewsWire

Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D.

Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon's investigational AT-1501 ...

1 year ago - GlobeNewsWire